Cleerly vs Elucid

Coronary plaque on CCTA, billed under Category I CPT 75577 since January 2026, is the ground these two share. Medicare pays the performing site about $1,012 nationally for it in imaging centers, and Elucid's own per-scan fee is unpublished. Cleerly adds ischemia likelihood through Cleerly ISCHEMIA, PowerScribe integration, and Cleerly Plaque (K261210, July 2026).

Elucid's PlaqueIQ (K241524, September 2024) works as a service. Per the 2024 release, trained analysts segment a 3D model of the arteries, and turnaround is unpublished. The Lesion Inspection Tool, on sale since April 2026, covers coronary and carotid plaque. Elucid's FFR-CT analysis is pending FDA review, and the FDA record frames the cleared claim as plaque quantification to support clinicians.

Ischemia likelihood from the same scan is a reason to choose Cleerly, and on that need Elucid loses. Practices that also want carotid plaque read and will send images out are Elucid's customers.